Calcitonin gene related peptide (CGRP) in pain and migraine: a mini-review

Abstract

In this mini-review the role of CGRP (Calcitonin Gene-Related Peptide) in pain processing pathways and in migraine are discussed. Physiology and pathophysiology of CGRP in non-headache pain as somatic, visceral, inflammatory and neuropathic pain are evaluated. Results are conflicting and it appears that there are no clinical trials establishing the role of CGRP as a sensory pain modulator in non-headache pain. In contrast, the four new anti-CGRP antibodies developed for the prevention of migraine attacks reduce headache frequency in half of patients by 50%. Safety and tolerability during the 3-months trials appear good but long-term safety is unknown. Expected pricing and the potential market size of $5 billion to $10 billion are discussed.

Introduction

Calcitonin Gene Related Peptide (CGRP) is a 37 amino-acid neuropeptide identified in 1982 by Amara et al.1 They found that alternate splicing of the gene for calcitonin (CT) produced a very different peptide designated as alpha-CGRP. Subsequently, a novel gene coding a homologous peptide was discovered. This peptide beta-CGRP differs from alpha-CGRP by a single amino acid in the rat and 3 amino acids in humans.2 The biological activity of these 2 forms of CGRP is nearly identical but based on receptor binding assays and in vitro bioassays there are small differences in potency.2 Alpha- and beta CGRP belong to the calcitonin (CT) receptor family of peptides. These also include procalcitonin(proCT), calcitonin (CT), adrenomedullin (AM), amylin (AMY), intermedin (AM2) as well as the carboxy-terminal fragments CGRP(18-37) and CGRP(19-37). These fragments have been found in the spinal cord of the rat; the CGRP(19-37) fragment is an antagonist of the CGRP receptor.3,4

The CGRP receptor is atypical among the family of G protein-coupled receptors because the functional receptor is composed from the heterodimerization of 2 peptides.5 These 2 peptides, the receptor activity-modifying protein 1 (RAMP1) accessory protein and the calcitonin receptor-like receptor (CLR) protein are required to efficiently couple to the Gs unit.5-7 Moreover CGRP has affinity to other receptors, including the Gs protein 1 (AMY1) receptor, which is also a heterodimer containing RAMP1 but with the calcitonin receptor (CT) protein.6,8 Calcitonin gene related peptide’s affinity for AMY1 is comparable with the CGRP receptor and has been proposed as a second CGRP receptor site.6 In addition, to its role as a pain modulator in the somatosensory system, CGRP is also an extremely potent vasodilator. Vascular beds, including the mesenteric and meningeal vasculatures, are rich in CGRP receptors. There is evolving evidence, that CGRP plays a critical role in the trigeminovascular origin of the pathogenesis of migraine.9,10

In this mini-review the role of CGRP in pain-processing pathways and particularly in migraine are discussed. The recent results of phase 1 and 2 and 3 clinical trials with monoclonal antibodies directed at CGRP, or its receptor, will be evaluated too.

CGRP as a pain modulator in non-headache pain

CGRP is primarily released from sensory nerves and is involved in pain pathways in this way. It is localized to C and A, delta sensory fibers of specialized peripheral sensory neurons, known as nociceptors. Activation of these nociceptors and the processing of information they convey, provide a rich diversity of pain qualities.12

The regulation of CGRP synthesis is still poorly understood. CGRP synthesis is known to be upregulated in models of nerve damage, such as peripheral axotomy, and it is believed that synthesis of the peptide is enhanced in tissues that are undergoing an inflammatory response.13 The realization that CGRP was present in sensory nerves led to studies with the chili extract capsaicin, which is now known to activate transient receptor potential vanilloid 1 (TRPV1) receptors, commonly found on sensory C- and A, delta fibers. Capsaicin has long been known to cause pain and redness on acute application. Thus, its ability to release CGRP and the co-localized neuropeptide substance P was not a surprise.14-16

In the periphery, the primaryafferent nociceptors terminate as fine nerve endings, innervating peripheral structures.17 Tissue injury results in the release of numerous proinflammatory mediators from the injured cells, mast cells, leukocytes and the nerve terminals. These substances include the tachykinins, bradykinin, prostaglandins, serotonin, histamine, as well as the release of CGRP and substance P from the nerve endings.17 These proinflammatory mediators can directly activate the nociceptors. Generate action potentials, or facilitate the firing of the nociceptors, resulting in peripheral sensitization and hyperalgesia. Activation of a free nerve ending can produce an axon reflex action, which causes the release of CGRP and substance P from adjacent free endings of the same axon, resulting in the release of additional proinflammatory mediators. This in turn can further excite adjacent nerve endings and thus propagate an expanding area of neurogenic inflammation, indicated by the erythematous flare response.17-20

CGRP in somatic pain

Several studies have shown a relationship between CGRP levels...
and somatic pain and pain intensity. In chronic knee pain, due to osteoarthritis elevated CGRP levels were detected in serum and synovial fluid in patients (n=65) compared with controls (n=21). Serum CGRP levels were positively correlated with pain intensity. Chronic low back pain patients, due to osteoarthritis, (n=32), showed decreased CGRP levels four months after acupressure pain treatment compared to baseline. No decrease was found in patients who received sham treatment(n=29). In addition, studies using immunofluorescence of skin biopsies reported decreased CGRP after acupuncture treatment of osteoarthritis patients (n=6). Immunohistochemistry analysis of synovial tissue from fossa acetabuli, showed increased CGRP levels compared to controls(n=9) and (n=67), respectively. Another study reported higher levels of CGRP in hip synovium from osteoarthritis patients compared with femoral neck patients (n=62). Higher CGRP levels were also found in synovial tissues from temporomandibular joint pain patients compared with controls. This study also reported positive correlations between pain and CGRP levels (n=5). Biopsies from knee joint ligaments showed no difference in CGRP nerve density between patients and non-arthritis. (n=15). In patients with osteoarthritis CGRP concentration in cerebrospinal fluids was decreased compared to controls(n=35). In patients suffering from chronic pain due to degenerative disc disease, disc biopsies showed increased CGRP, compared to post-mortem control discs (n=22). Biopsies from intervertebral discs in patients contained CGRP-IR (immunoreactive) nerve fibers. Whiplash injury patients and disc herniation patients showed increased blood levels of CGRP.

CGRP in visceral pain

Immunofluorescence based analysis of peritoneal fluid obtained during laparoscopy in patients with endometriosis showed increased CGRP levels compared to peritoneal fluid from controls without endometriosis. Patients with non-erosive reflux disease and functional dyspepsia were investigated by enzyme-and radioimmunoassay. No differences in CGRP reactivity of mucosal biopsies were found compared to controls. Plasma CGRP levels were studied in patients with suspected or definite myocardial infarction at admission at a coronary care unit. This study revealed no differences in CGRP levels between patients with and without acute myocardial infarction and no difference between patients with pain and those without pain.

CGRP in inflammatory pain

ELISA or dernal microdiyalisate from volar forearm studies showed elevated blood CGRP levels in 10 healthy volunteers with capsacin-induced pain. No CGRP release was detected via dernal microdiyalisate after electrical stimulation in the same area. Patients with non-erosive reflux disease and functional dyspepsia were investigated by enzyme-and radioimmunoassay. No differences in CGRP reactivity of mucosal biopsies were found compared to controls. Plasma CGRP levels were studied in patients with suspected or definite myocardial infarction at admission at a coronary care unit. This study revealed no differences in CGRP levels between patients with and without acute myocardial infarction and no difference between patients with pain and those without pain.

CGRP in neuropathic pain

Radioimmunoassay showed higher serum CGRP levels in 19 patients with complex regional pain syndrome (CRPS) compared to controls. The difference was normalized after a 9-month pain management therapy. In contrast, another study found decreased CGRP levels in chronic CRPS patients (n=12) compared with healthy controls. No correlation between pain and CGRP levels was found in either study. In post-herpetic neuralgia increased CGRP expression in the affected skin compared with skin from a contralateral side in the same patient was reported by using immunofluorescence analyses of skin biopsies. No difference in CGRP expression was found between patients with chronic pain due to nerve injury after hand surgery and controls. The immunochemistry of peripheral nerve biopsies from patients with Morton’s neuroma, which results in neuropathic pain, showed increased amount of CGRP in patients compared with controls. Attal et al. investigated 152 patients with persistent neuropathic pain of whom 68 were treated with botulinum toxin A and 66 received placebo. CGRP was analyzed in skin biopsies using ELISA at week 1 and 4 in 23 patients, who received botulinum toxin A and in 17 patients, ho received placebo. No difference between the groups was found.

CGRP antagonists and antibodies and clinical trials

Non-headache pain

There are no clinical trials on CGRP antagonists and antibodies for the treatment of non-headache pain by searching Pubmed and Embase, despite 35 years of CGRP research. Search on ClinicalTrials.gov for current CGRP antagonists and antibodies for the treatment of non-headache pain only yields three studies.

The acute effect of PT-04427429 anti-CGRP monoclonal antibody on attenuation of flare response after capsaicin challenge was studied in a double blind randomized, placebo controlled trial in male healthy volunteers, using EMLA cream as a positive control. However, primary outcome was mean blood perfusion and no pain perceptions were studied. A phase 2 randomized, double blind, placebo controlled trial in patients with mild to moderate osteoarthritis knee pain failed to demonstrate efficacy of LY2951742, monoclonal antibody to CGRP.

Cluster headache and migraine

Recently, there was a lot of attention in the mainstream press regarding the role of anti-CGRP drugs in the prevention of the migraine attacks. CGRP is highly prevalent as a neurotransmitter in the trigeminovascular system. CGRP levels are found in high levels during migraine attacks. Maximum increases in plasma levels of CGRP are reached within 2 hours of the onset of the attacks and can be reverted by treatment with the tryptans. CGRP levels measured in peripheral blood outside migraine attacks and in the absence of symptomatic medication have been shown to be increased in chronic migraine patients. Increased CGRP levels were able to predict the response to onabotulinumtoxin A treatment and were reduced 1 month after onabotulinum type A therapy. Migraine is primarily a complex disorder involving local vasodilation of intracranial, extracerebral blood vessels and simultaneous stimulation of surrounding trigeminal sensory nerve pathways that result in headache.

It is believed that "activation" of the trigeminovascular system causes release of various vasodilators, especially CGRP, that is...
supposed to induce the pain response although hard evidence is not available. As depicted above, the relationship between CGRP and pain perception has been documented badly in decades of research in non-headache pain. Nevertheless, the trigeminovascular release of CGRP during a migraine attack is accompanied by decreased levels of the neurotransmitter serotonin. Serotonin agonists as the tryptans (Sumatriptan, Imigran) are vasoconstrictors. They bring the elevated levels of CGRP to normal. Tryptans and the ergot alkaloids have been proven efficacious in the treatment of migraine. The ergot alkaloids have partial agonist activity at serotonin and are antagonists at adrenergic, tryptaminergic and dopaminergic receptors. Their relationship with CGRP is not well known. Varying levels of ovarian hormones, especially estrogen, influence the serotonin neurotransmitter system and CGRP levels making women more proposed to migraine attacks.

Migraine prevention and CGRP antibodies

Prevention is a key component of migraine. While numerous preventive options exist, each is hampered by either troublesome side effects or insufficient efficacy. For that reason CGRP has moved to the forefront as a neuropeptide control to migraine prevention. Six small molecule receptor antagonists were shown to be effective for the acute treatment of migraine. Two were stopped for hepatotoxicity. At present, four CGRP monoclonal antibodies completed phase 2 trials or are in phase 3 trials. These results will be discussed now.

Galcanezumab (LY 2951427)

The first phase 2 clinical trial results to be published were for Eli-Lilly’s galcanezumab. Patients with episodic migraine (4 to 14 headaches in a 4 week baseline period) were randomized to galcanezumab 150 mg s.c. versus placebo every 2 weeks for 12 weeks. Primary efficacy endpoint was the change in number of migraine headache days (MHDs) during the third 4-week treatment period (weeks 9-12). The mean change in MHDs was significantly different in the galcanezumab group compared to the placebo group (-4.2 versus -3.0 days; p=0.003). Galcanezumab was tested in the REGAIN trial in patients with chronic migraine. At doses of 120 mg s.c. per month (n=278) or 240 mg s.c. per month the active drug proved superior to placebo (n=558). At months 1 to 3 the overall mean change in MHDs was -2.74 for placebo, -4.83 for the 120 mg dose and -4.62 for the 240 mg dose (p<0.001 for both doses versus placebo). At baseline all participants had 15 MHDs per month with medication use. Almost twice as many participants in the drug groups (27%) experienced a 50% reduction in monthly MHDs compared with the placebo group (15.4%; p<0.001). Participants tolerated the active treatment well with few dropouts. Most of the dropouts were in the placebo group (49 of 558).

The 120 mg s.c. dose was pinpointed as the lowest effective dose in a phase 2b study comparing 120 mg versus 300 mg doses (n=410). Only the 120 mg met the primary objective of “posterior probability of greater improvement” (Bayesian analysis) MHDs, than the specified thresholds of 95% for mean change versus placebo. The posterior probability was 99.6% for the 120 mg group, which had mean reductions of 4.8 MHDs by week 12 versus reductions of 3.7 MHDs in the placebo group. Common treatment related adverse effects (AEs) for the galcanezumab group included injection-side pain, upper respiratory tract infections, nasopharyngitis and abdominal pain. Remember as depicted above, galcanezumab failed in a phase 2 trial in patients with mild to moderate osteoarthritis knee pain. Eli-Lilly has submitted their results, sampled in the REGAIN 7-9, Evolve1 and Evolve2 trials (n=2900) for FDA approval on December 12th 2017.

Epinizumab (ALD-403)

ALD-403 (Alder Biopharmaceuticals) is administered intravenously, aiming at a direct physiological effect with rapidly efficacious dosing. Patients with episodic migraine (5-14 MHDs per month) were randomized to either a single dose of monthly 1000 mg or placebo. The primary endpoint was the change in number of MHDs during weeks 5 to 8 compared to the baseline period. Epinitumab resulted in significantly fewer migraine days compared to placebo (-5.6 vs-4.6 days; p=0.03).

Fremazenzumab (TEV-48215 or LBR-101)

Teva Pharmaceuticals investigated fremazenzumab in two trials. One for patients with high-frequency migraine and the other for patients with chronic migraine. Patients with 8-14 MHDs in a 4 week baseline period were randomized to subcutaneous injections of either 225 mg or 675 mg or placebo every 4 weeks for 12 weeks. Primary endpoint was the change in number of MHDs during the third 4-week treatment period (weeks 9-12) compared to the baseline period. The reduction in MHDs was significantly greater for both the fremazenzumab 225 mg (-6.27 vs -3.46 days; p=0.001) and 675 mg doses (-6.09 vs-3.46 days; p=0.001). Of note, in contrast to the previous two studies, patients were not excluded for a migraine preventive, provided the dose was stable for 2 months before screening. In the chronic migraine trial, patients were randomized to either placebo or one of two fremazenzumab doses given every 4 weeks for 12 weeks; 675 mg loading dose, followed by two 225 mg doses or three doses of 900 mg. Primary endpoint was change in hours of headache of any severity during the third 4-week treatment period (weeks 9-12) compared to the baseline period. Mean reduction in headache hours of any severity was significantly greater compared to placebo for both the fremazenzumab 675 mg/225 mg (-5.98 vs-37.1 hour; p=0.03) and 900 mg doses (-67.5 vs-37.1 hour; p=0.005). Use of up to two preventives was permitted, provided the doses were stable for at least 3 months before the start of the study.

Erunumab (AMG-334)

While galcanezumab, epinizumab and fremazenzumab are CGRP monoclonal antibodies, AMG-334 (Amgen) or erenumab is the only CGRP receptor monoclonal antibody up until now. Patients with episodic migraine (4-14 MHDs in a 4 week baseline period) were randomized to either placebo or one of three doses of erenumab (7,14, or 70 mg).c every 4 weeks for 12 weeks. Primary endpoint was the change in number of MHDs during the third 4-week treatment period. Mean change in MHDs was significantly different from the placebo-group, only for the highest dose, erenumab 70 mg (-3.4 vs 2.3 days; p=0.02).

Pharmacology evaluation of the CGRP antibodies

Initial safety and tolerability for the anti-CGRP monoclonal antibodies appears good. Immunogenecity by inducing anti-drug antibodies is not a problem during all of these 3-months trials, so far. As all the CGRP monoclonal antibodies have a long biological half-life of 31 days, the long-term safety is entirely unknown at this time. CGRP has a complex physiological function than but merely of
a sensory pain modulator. CGRP receptors are found in the nervous, vascular system, adrenals, kidneys, pancreas and bone. The effects of chronic CGRP antagonism on these organs are not known. Since the CGRP antibodies have a very long biological half-life any untoward effects can not be reversed quickly.\(^{16}\) Though developed by four different companies, he preventive drugs are fairly similar. They are injected once a month and seem to reduce headache frequency in half of patients by 50%. An oral CGRP antagonist developed by Allergan, atogepant, is in mid-stage clinical trials. The first CGRP preventive migraine drug might come on the market mid-2018. Pricing is expected to start at $ 8,500 a year, comparable to the pricing of the cholesterol-controlling PCSK9 inhibitors. About seven million patients would likely get the treatment resulting in a $5 billion to $10 billion potential market size.\(^{16}\)

**Discussion**

A review of the role of CGRP as a sensory pain modulator yields conflicting results in somatic, visceral, inflammatory and neuropathic pain. It appears there are no clinical trials establishing the role of CGRP as a sensory pain modulator in non-headache pain despite 35 years of research. However, the new anti-CGRP monoclonal antibodies developed for the prevention of migraine show highly concordant results. All of these 4 Anti-CGRP antibodies reduce headache frequency in half of patients by 50%. This is rather surprising compared to the results in non-headache pain. So far, this is not explained, but it suggests different mechanisms in pain perception in migraine and non-headache pain. Short-time safety and tolerability of the anti-CGRP antibodies appear good but long-term safety is unknown. The filing for FDA approval by four different pharmaceutical companies looks like a race against the clock for pole position in a $5 billion to $10 billion potential market size.\(^{16}\)

**Acknowledgment**

None.

**Conflict of interests**

None.

**References**

Calcitonin gene related peptide (CGRP) in pain and migraine: a mini-review


65. Court E. New migraine drugs have promise- and a $ 8,500 price tag. Market Watch; 2017.